Abbvie Inc. Common Stock (ABBV) 59.62 $ABBV Pio
Post# of 64074
Posted On: 03/03/2015 7:45:57 PM
Abbvie Inc. Common Stock (ABBV) 59.62 $ABBV
Pioneer Fundamental Growth Fund: Why Is It Revving Up?
at Investor's Business Daily - 55 mins ago
Stock mutual fund managers Andrew Acheson and Paul Cloonan have been kicking it into a higher gear at Pioneer Fundamental Growth Fund. The 16.61% average annual return of their $2.4 billion fund ranked in the top 27% of its large-cap growth rivals...
SBUX: 94.00 (-0.22), ESRX: 84.35 (-0.58), LNKD: 265.54 (-3.88), GILD: 102.79 (-1.04), ABBV: 59.62 (-0.84), AAPL: 129.36 (+0.27), CELG: 118.47 (-1.84)
Amgen: The Best Biotech Stock You Don't Own
Dan Strack - at Seeking Alpha - 2 hrs 40 mins ago
BIIB: 412.79 (-3.00), GILD: 102.79 (-1.04), PFE: 34.56 (-0.21), MRK: 58.34 (-0.24), AMGN: 158.56 (-1.07), ABBV: 59.62 (-0.84), GSK: 47.71 (-0.22), BMY: 61.92 (-0.38), HSP: 87.71 (+0.04), NVS: 99.06 (-1.01), CELG: 118.47 (-1.84)
10 Dandy Dividend Healthcare Dogs Hail 14% February Upsides
Fredrik Arnold - at Seeking Alpha - Tue Mar 03, 5:28AM CST
KND: 22.09 (+0.15), VIVO: 20.00 (-0.04), PETS: 15.13 (-0.32), PFE: 34.56 (-0.21), AMGN: 158.56 (-1.07), GSK: 47.71 (-0.22), MSA: 49.71 (-0.47), PDLI: 7.02 (+0.01), BAX: 69.42 (-0.54), AZN: 68.28 (-0.45), MRK: 58.34 (-0.24), STJ: 67.60 (-0.76), TRIB: 18.43 (+0.46), TEVA: 56.46 (-0.70), ABBV: 59.62 (-0.84), THRX: 19.56 (+0.34), SNY: 48.08 (-0.21)
The Dividend House DGI Portfolio: The Good, The Bad, And The Ugly
Dividend House - at Seeking Alpha - Mon Mar 02, 11:51PM CST
KMI: 41.09 (+0.26), ABT: 47.09 (-0.13), HAS: 62.72 (-0.43), GE: 25.86 (-0.25), MAIN: 31.23 (+0.15), HTGC: 14.48 (-1.02), TCAP: 24.53 (+0.25), DLR: 66.72 (-0.22), PFE: 34.56 (-0.21), WMT: 83.37 (-0.59), WFC: 55.45 (-0.10), UL: 44.05 (-0.15), O: 50.55 (-0.10), BMY: 61.92 (-0.38), VOD: 34.62 (+0.04), DEO: 117.22 (-0.54), TUP: 71.11 (-0.50), WTR: 26.45 (+0.07), WBA: 83.21 (-0.41), CBRL: 151.76 (+1.33), MAT: 26.90 (+0.34), OHI: 40.26 (-0.28), ABBV: 59.62 (-0.84), AFL: 62.28 (-0.29), BBL: 49.30 (-0.10), CMCSA: 59.96 (+0.09), OMI: 35.33 (-0.55)
Is Now The Time To Pounce On The Pot Business?
Nicholas Kitonyi - at Seeking Alpha - Mon Mar 02, 2:09PM CST
GWPH: 79.55 (-0.73), ABBV: 59.62 (-0.84), BMY: 61.92 (-0.38)
Bristol Myers' HCV Cocktail Has Gilead, AbbVie In Its Crosshairs
Shock Exchange - at Seeking Alpha - Mon Mar 02, 9:32AM CST
GILD: 102.79 (-1.04), ABBV: 59.62 (-0.84), BMY: 61.92 (-0.38)
These Stocks Just Raised Their Dividends
Eric Volkman, The Motley Fool - Motley Fool - Mon Mar 02, 7:03AM CST
With all the dividend raises occurring in this early part of the year, several likely suspects have decided to get in on the action. These are the Dividend Aristocrats, the companies that have raised their distributions at least once annually for a...
KO: 42.95 (-0.25), ABT: 47.09 (-0.13), ABBV: 59.62 (-0.84), CL: 70.68 (-0.33)
Billionaire George Soros Just Dumped These 3 Dividend Stocks
George Budwell, The Motley Fool - Motley Fool - Sun Mar 01, 9:55AM CST
Because billionaire investors can have a disproportionately large impact on how markets behave in the short term, their buys and sells tend to be closely scrutinized. And controversial hedge-fund manager George Soros is one of the most widely watched...
GILD: 102.79 (-1.04), MRK: 58.34 (-0.24), AZN: 68.28 (-0.45), TEVA: 56.46 (-0.70), ABBV: 59.62 (-0.84)
Achillion: The Dark Side
Kanak Kanti De - at Seeking Alpha - Fri Feb 27, 5:45AM CST
GILD: 102.79 (-1.04), ACHN: 12.14 (-0.21), ABBV: 59.62 (-0.84)
Cyberonics Soars On Earnings Beat, Tax Inversion Deal
at Investor's Business Daily - Thu Feb 26, 12:58PM CST
Shares of Cyberonics (CYBX) gapped up to a record high Thursday after the company reported better than expected earnings growth and said it is merging with Italy's Sorin and moving its headquarters to Europe despite new Treasury rules intended to...
ABMD: 60.15 (-2.04), QSR: 43.62 (-1.05), MDT: 78.03 (-0.80), BAX: 69.42 (-0.54), SHPG: 238.90 (+2.48), EW: 134.58 (-1.27), ABBV: 59.62 (-0.84), CYBX: 70.36 (+0.21)
Biotech Head-to-Head: Gilead vs. Celgene
Todd Campbell and Michael Douglass, The Motley Fool - Motley Fool - Thu Feb 26, 11:03AM CST
It's Fool versus Fool on this health care edition of Industry Focus. Michael Douglass argues for Gilead Sciences , while Todd Campbell goes to bat for Celgene . Which of these biotech giants is the better investment? Both companies have had...
GILD: 102.79 (-1.04), ABBV: 59.62 (-0.84), CELG: 118.47 (-1.84)
Cyberonics, Sorin Plan to Merge in Latest Tax Inversion Deal
at The Street - Thu Feb 26, 10:54AM CST
Medical device manufacturers Cyberonics and Sorin will join forces and move their headquarters to the U.K. in a deal propelled by the search for lower corporate taxes.
SHPG: 238.90 (+2.48), ABBV: 59.62 (-0.84), CYBX: 70.36 (+0.21)
New Parkinson's drug cleared in Europe
Seeking Alpha - at Seeking Alpha - Thu Feb 26, 9:23AM CST
ADMS: 17.25 (-0.05), ACOR: 35.20 (+0.19), NDRM: 12.48 (-0.71), XNPT: 7.10 (-0.02), IPXL: 39.93 (-0.52), ABBV: 59.62 (-0.84), TEVA: 56.46 (-0.70), SNY: 48.08 (-0.21), PRTA: 25.63 (-0.84)
FDA accepts Teva's NDA for abuse-deterrent opioid
Seeking Alpha - at Seeking Alpha - Wed Feb 25, 8:42AM CST
MNK: 114.85 (-3.97), LCI: 62.27 (-0.65), ACT: 296.23 (-1.08), EGLT: 15.36 (+0.03), ZGNX: 1.67 (-0.02), PFE: 34.56 (-0.21), ABBV: 59.62 (-0.84), TEVA: 56.46 (-0.70), ALKS: 72.80 (+1.33), ACUR: 0.82 (-0.06)
Updating My Price Target On Gilead Sciences
Alexander J. Poulos - at Seeking Alpha - Tue Feb 24, 12:41PM CST
JNJ: 102.34 (-0.88), ESRX: 84.35 (-0.58), GILD: 102.79 (-1.04), PFE: 34.56 (-0.21), MRK: 58.34 (-0.24), ABBV: 59.62 (-0.84)
Express Scripts Earnings Set the Stage for Growth
Todd Campbell, The Motley Fool - Motley Fool - Tue Feb 24, 10:19AM CST
Source: Express Scripts. As healthcare payers hunt for ways to rein in ever-higher drug costs, the pharmacy benefit manager Goliath Express Scripts Holding Company reported better-than-expected fourth-quarter results, and full year 2014...
ESRX: 84.35 (-0.58), UNH: 112.86 (-1.54), ABBV: 59.62 (-0.84)
AbbVie: Attractive Valuation, Growth Prospects & Yield
Bret Jensen - at Seeking Alpha - Tue Feb 24, 8:39AM CST
ABBV: 59.62 (-0.84)
Gilead: All Is Still Well Down On The Farm
Shock Exchange - at Seeking Alpha - Tue Feb 24, 7:44AM CST
GILD: 102.79 (-1.04), ABBV: 59.62 (-0.84)
Can-Fite's A3AR Biomarker Targets Patients For Highest Efficacy In Phase III Trial
Sharon di Stefano - Seeking Alpha - Tue Feb 24, 7:40AM CST
Rheumatology, a sub-specialty of internal medicine, deals with problems in joints, soft and connective tissue, inflammation of blood vessels and autoimmune disease. Due to the last category and because it underlies the occurrence of rheumatoid...
CANF: 4.50 (-0.15), JNJ: 102.34 (-0.88), AMGN: 158.56 (-1.07), ABBV: 59.62 (-0.84)
Abbvie's 'One Trick Pony' Faces Patent Expiration In 2016
Shock Exchange - at Seeking Alpha - Tue Feb 24, 7:21AM CST
GILD: 102.79 (-1.04), ABBV: 59.62 (-0.84)
Pioneer Fundamental Growth Fund: Why Is It Revving Up?
at Investor's Business Daily - 55 mins ago
Stock mutual fund managers Andrew Acheson and Paul Cloonan have been kicking it into a higher gear at Pioneer Fundamental Growth Fund. The 16.61% average annual return of their $2.4 billion fund ranked in the top 27% of its large-cap growth rivals...
SBUX: 94.00 (-0.22), ESRX: 84.35 (-0.58), LNKD: 265.54 (-3.88), GILD: 102.79 (-1.04), ABBV: 59.62 (-0.84), AAPL: 129.36 (+0.27), CELG: 118.47 (-1.84)
Amgen: The Best Biotech Stock You Don't Own
Dan Strack - at Seeking Alpha - 2 hrs 40 mins ago
BIIB: 412.79 (-3.00), GILD: 102.79 (-1.04), PFE: 34.56 (-0.21), MRK: 58.34 (-0.24), AMGN: 158.56 (-1.07), ABBV: 59.62 (-0.84), GSK: 47.71 (-0.22), BMY: 61.92 (-0.38), HSP: 87.71 (+0.04), NVS: 99.06 (-1.01), CELG: 118.47 (-1.84)
10 Dandy Dividend Healthcare Dogs Hail 14% February Upsides
Fredrik Arnold - at Seeking Alpha - Tue Mar 03, 5:28AM CST
KND: 22.09 (+0.15), VIVO: 20.00 (-0.04), PETS: 15.13 (-0.32), PFE: 34.56 (-0.21), AMGN: 158.56 (-1.07), GSK: 47.71 (-0.22), MSA: 49.71 (-0.47), PDLI: 7.02 (+0.01), BAX: 69.42 (-0.54), AZN: 68.28 (-0.45), MRK: 58.34 (-0.24), STJ: 67.60 (-0.76), TRIB: 18.43 (+0.46), TEVA: 56.46 (-0.70), ABBV: 59.62 (-0.84), THRX: 19.56 (+0.34), SNY: 48.08 (-0.21)
The Dividend House DGI Portfolio: The Good, The Bad, And The Ugly
Dividend House - at Seeking Alpha - Mon Mar 02, 11:51PM CST
KMI: 41.09 (+0.26), ABT: 47.09 (-0.13), HAS: 62.72 (-0.43), GE: 25.86 (-0.25), MAIN: 31.23 (+0.15), HTGC: 14.48 (-1.02), TCAP: 24.53 (+0.25), DLR: 66.72 (-0.22), PFE: 34.56 (-0.21), WMT: 83.37 (-0.59), WFC: 55.45 (-0.10), UL: 44.05 (-0.15), O: 50.55 (-0.10), BMY: 61.92 (-0.38), VOD: 34.62 (+0.04), DEO: 117.22 (-0.54), TUP: 71.11 (-0.50), WTR: 26.45 (+0.07), WBA: 83.21 (-0.41), CBRL: 151.76 (+1.33), MAT: 26.90 (+0.34), OHI: 40.26 (-0.28), ABBV: 59.62 (-0.84), AFL: 62.28 (-0.29), BBL: 49.30 (-0.10), CMCSA: 59.96 (+0.09), OMI: 35.33 (-0.55)
Is Now The Time To Pounce On The Pot Business?
Nicholas Kitonyi - at Seeking Alpha - Mon Mar 02, 2:09PM CST
GWPH: 79.55 (-0.73), ABBV: 59.62 (-0.84), BMY: 61.92 (-0.38)
Bristol Myers' HCV Cocktail Has Gilead, AbbVie In Its Crosshairs
Shock Exchange - at Seeking Alpha - Mon Mar 02, 9:32AM CST
GILD: 102.79 (-1.04), ABBV: 59.62 (-0.84), BMY: 61.92 (-0.38)
These Stocks Just Raised Their Dividends
Eric Volkman, The Motley Fool - Motley Fool - Mon Mar 02, 7:03AM CST
With all the dividend raises occurring in this early part of the year, several likely suspects have decided to get in on the action. These are the Dividend Aristocrats, the companies that have raised their distributions at least once annually for a...
KO: 42.95 (-0.25), ABT: 47.09 (-0.13), ABBV: 59.62 (-0.84), CL: 70.68 (-0.33)
Billionaire George Soros Just Dumped These 3 Dividend Stocks
George Budwell, The Motley Fool - Motley Fool - Sun Mar 01, 9:55AM CST
Because billionaire investors can have a disproportionately large impact on how markets behave in the short term, their buys and sells tend to be closely scrutinized. And controversial hedge-fund manager George Soros is one of the most widely watched...
GILD: 102.79 (-1.04), MRK: 58.34 (-0.24), AZN: 68.28 (-0.45), TEVA: 56.46 (-0.70), ABBV: 59.62 (-0.84)
Achillion: The Dark Side
Kanak Kanti De - at Seeking Alpha - Fri Feb 27, 5:45AM CST
GILD: 102.79 (-1.04), ACHN: 12.14 (-0.21), ABBV: 59.62 (-0.84)
Cyberonics Soars On Earnings Beat, Tax Inversion Deal
at Investor's Business Daily - Thu Feb 26, 12:58PM CST
Shares of Cyberonics (CYBX) gapped up to a record high Thursday after the company reported better than expected earnings growth and said it is merging with Italy's Sorin and moving its headquarters to Europe despite new Treasury rules intended to...
ABMD: 60.15 (-2.04), QSR: 43.62 (-1.05), MDT: 78.03 (-0.80), BAX: 69.42 (-0.54), SHPG: 238.90 (+2.48), EW: 134.58 (-1.27), ABBV: 59.62 (-0.84), CYBX: 70.36 (+0.21)
Biotech Head-to-Head: Gilead vs. Celgene
Todd Campbell and Michael Douglass, The Motley Fool - Motley Fool - Thu Feb 26, 11:03AM CST
It's Fool versus Fool on this health care edition of Industry Focus. Michael Douglass argues for Gilead Sciences , while Todd Campbell goes to bat for Celgene . Which of these biotech giants is the better investment? Both companies have had...
GILD: 102.79 (-1.04), ABBV: 59.62 (-0.84), CELG: 118.47 (-1.84)
Cyberonics, Sorin Plan to Merge in Latest Tax Inversion Deal
at The Street - Thu Feb 26, 10:54AM CST
Medical device manufacturers Cyberonics and Sorin will join forces and move their headquarters to the U.K. in a deal propelled by the search for lower corporate taxes.
SHPG: 238.90 (+2.48), ABBV: 59.62 (-0.84), CYBX: 70.36 (+0.21)
New Parkinson's drug cleared in Europe
Seeking Alpha - at Seeking Alpha - Thu Feb 26, 9:23AM CST
ADMS: 17.25 (-0.05), ACOR: 35.20 (+0.19), NDRM: 12.48 (-0.71), XNPT: 7.10 (-0.02), IPXL: 39.93 (-0.52), ABBV: 59.62 (-0.84), TEVA: 56.46 (-0.70), SNY: 48.08 (-0.21), PRTA: 25.63 (-0.84)
FDA accepts Teva's NDA for abuse-deterrent opioid
Seeking Alpha - at Seeking Alpha - Wed Feb 25, 8:42AM CST
MNK: 114.85 (-3.97), LCI: 62.27 (-0.65), ACT: 296.23 (-1.08), EGLT: 15.36 (+0.03), ZGNX: 1.67 (-0.02), PFE: 34.56 (-0.21), ABBV: 59.62 (-0.84), TEVA: 56.46 (-0.70), ALKS: 72.80 (+1.33), ACUR: 0.82 (-0.06)
Updating My Price Target On Gilead Sciences
Alexander J. Poulos - at Seeking Alpha - Tue Feb 24, 12:41PM CST
JNJ: 102.34 (-0.88), ESRX: 84.35 (-0.58), GILD: 102.79 (-1.04), PFE: 34.56 (-0.21), MRK: 58.34 (-0.24), ABBV: 59.62 (-0.84)
Express Scripts Earnings Set the Stage for Growth
Todd Campbell, The Motley Fool - Motley Fool - Tue Feb 24, 10:19AM CST
Source: Express Scripts. As healthcare payers hunt for ways to rein in ever-higher drug costs, the pharmacy benefit manager Goliath Express Scripts Holding Company reported better-than-expected fourth-quarter results, and full year 2014...
ESRX: 84.35 (-0.58), UNH: 112.86 (-1.54), ABBV: 59.62 (-0.84)
AbbVie: Attractive Valuation, Growth Prospects & Yield
Bret Jensen - at Seeking Alpha - Tue Feb 24, 8:39AM CST
ABBV: 59.62 (-0.84)
Gilead: All Is Still Well Down On The Farm
Shock Exchange - at Seeking Alpha - Tue Feb 24, 7:44AM CST
GILD: 102.79 (-1.04), ABBV: 59.62 (-0.84)
Can-Fite's A3AR Biomarker Targets Patients For Highest Efficacy In Phase III Trial
Sharon di Stefano - Seeking Alpha - Tue Feb 24, 7:40AM CST
Rheumatology, a sub-specialty of internal medicine, deals with problems in joints, soft and connective tissue, inflammation of blood vessels and autoimmune disease. Due to the last category and because it underlies the occurrence of rheumatoid...
CANF: 4.50 (-0.15), JNJ: 102.34 (-0.88), AMGN: 158.56 (-1.07), ABBV: 59.62 (-0.84)
Abbvie's 'One Trick Pony' Faces Patent Expiration In 2016
Shock Exchange - at Seeking Alpha - Tue Feb 24, 7:21AM CST
GILD: 102.79 (-1.04), ABBV: 59.62 (-0.84)
(0)
(0)Scroll down for more posts ▼